Role of IgE Bearing Cells in Chronic Idiopathic Urticaria

携带 IgE 的细胞在慢性特发性荨麻疹中的作用

• 批准号: 9360402
• 负责人: SARBJIT Singh SAINI
• 金额: $ 22.26万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-06-27 至 2019-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9360402
• 关键词: Allergens; Allergic; Allergic Disease; Allergic Reaction; Antibodies; Basophilic Cell; Basophils; Biological; Blood Circulation; Cell Count; Cell physiology; Cell surface; Cells; Chronic; Clinical; Clinical Trials; Clinical assessments; Diagnosis; Disease; Disease remission; Down-Regulation; Feedback; Frequencies; Half-Life; Heart Diseases; Hour; IgE; IgE Receptors; Individual; Laboratories; Link; Measures; Mediating; Monitor; Pathogenesis; Pathway interactions; Patients; Periodicity; Play; Quality of life; Receptor Activation; Role; Signs and Symptoms; Skin; Skin Tissue; Subcutaneous Injections; Symptoms; Testing; Therapeutic; Tissues; United States; Urticaria; Work; anti-IgE; anti-IgG; base; clinical remission; density; effective therapy; expectation; experience; insight; mast cell; new therapeutic target; omalizumab; peripheral blood; phase 3 study; public health relevance; rate of change; receptor expression; response

 DESCRIPTION (provided by applicant): Urticaria is a condition that has a lifetime likelihood of 25% in the United States and a significant proportion of these individuals will experience the disease in a cyclical form that lasts 1-10 years and for which no cause can be identified. If this condition occurs, the patient is given the diagnosis of chronic idiopathic urticaria (CIU). Theof condition can be severe and produce a reduction in the quality of life similar to that measured for heart diseases. At present, there is no known mechanism but recent studies have shown that the disease can be treated with non-aggregating, anti-IgE antibody (omalizumab). More remarkably, treatment with omalizumab leads to remission of active disease with a rapidity that is not consistent with expectations for changes in skin mast cells. There are numerous indications that basophils play a role in expression of this disease and the rate of clinical improvement on omalizumab is consistent with the timing of basophils changes seen in studies of allergic subjects during treatment with omalizumab. This proposal will directly test the hypothesis that changes in IgE-dependent functionality of basophils will be concordant with the rate of clinical improvement during treatment with omalizumab. This study will conduct a clinical trial of omalizumab therapy for patients with active CIU. This trial will be characterized by a hig temporal frequency of both clinical assessments and a variety of metrics of basophil and mast cell function.